Evidence map›Paper›PMID 36790533›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2023

The PER3

Hongyu Chen, Pingping Yang, Dan Yang, Dongsheng Wang, Mao Lu, Yadong Li, Zhiqiang Zhong, Jing Zhang, Zhen Zeng, Zhi Liu and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Biological clock regulation by theFrontiers in cell and developmental biology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Hongyu ChenSchool of Clinical Laboratory Science, Guizhou Medical University, Guiyang, Guizhou, 550004, People's Republic of China.
Pingping YangSchool of Clinical Laboratory Science, Guizhou Medical University, Guiyang, Guizhou, 550004, People's Republic of China.
Dan YangClinical Research Center, the Affiliated Hospital of Guizhou Medical University, No.9 Beijing Road, Guiyang, Guizhou, 550004, People's Republic of China.
Dongsheng WangDepartment of Laboratory Medicine, Sichuan Cancer Hospital and Institute, Chengdu, 610041, People's Republic of China.
Mao LuDepartment of Dermatovenereology, the First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, 610500, People's Republic of China.
Yadong LiClinical College, Guizhou Medical University, Guiyang, Guizhou, 550004, People's Republic of China.
Zhiqiang ZhongSchool of Clinical Laboratory Science, Guizhou Medical University, Guiyang, Guizhou, 550004, People's Republic of China.
Jing ZhangClinical Research Center, the Affiliated Hospital of Guizhou Medical University, No.9 Beijing Road, Guiyang, Guizhou, 550004, People's Republic of China.
Zhen ZengSchool of Clinical Laboratory Science, Guizhou Medical University, Guiyang, Guizhou, 550004, People's Republic of China.
Zhi LiuDepartment of Dermatovenereology, the Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550004, People's Republic of China.
Xiaohua ZengDepartment of Breast Cancer Center, Chongqing Key Laboratory for Intelligent Oncology in Breast Cancer (iCQBC), Chongqing University Cancer Hospital, Chongqing, People's Republic of China.
Xu JiaNon-Coding RNA and Drug Discovery Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, Sichuan, People's Republic of China.
Qinghe XingChildren's Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, People's Republic of China.
Ding'an ZhouClinical Research Center, the Affiliated Hospital of Guizhou Medical University, No.9 Beijing Road, Guiyang, Guizhou, 550004, People's Republic of China. 081023094@fudan.edu.cn.ORCID 0000-0002-6614-9321
Guiyang Medical University · CNChengdu Medical College · CNChildren's Hospital of Fudan University · CNChongqing University · CNFirst Affiliated Hospital of Chengdu Medical College · CNSichuan Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dyschromatosis universalis hereditaria (DUH) is a pigmentary genodermatosis characterized by a mixture of hyperpigmented and hypopigmented macules distributed randomly over the body. Although Sterile Alpha motif- and SH3 domain-containing protein 1 (SASH1) and ATP-binding cassette subfamily B, member 6 (ABCB6) have been identified as causative genes for this disorder, some cases involve unknown pathogenic genes. In this study, whole-exome sequencing, data analysis, and Sanger sequencing were utilized for a four-generation extended Chinese family with DUH. A single-nucleotide polymorphism (SNP) (c. 517C > T (p.P173S), rs772027021) variant in exon 5 of Period Circadian Regulator 3 (PER3) (NM_001289861) was detected in each affected individual of the DUH family; the c. 517C > T SNP of PER3 (PER3

Indexed as

HyperpigmentationMelaninsAnimalsHumansPedigreePeriod Circadian ProteinsPigmentationPigmentation DisordersPolymorphism, Single NucleotideSkin Diseases, GeneticZebrafishMelaninsPER3 protein, humanPeriod Circadian ProteinsDyschromatosis universalis hereditaria (DUH)Hyperpigmentation phenotypePER3 SNPSASH1 mutation

Identifiers

PMID36790533
OpenAlexW4320856905

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.